Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
News Type
News Topics
- (-) Cybersecurity (1)
- (-) Isotopes (5)
- (-) Neutron Science (5)
- (-) Polymers (3)
- (-) Space Exploration (1)
- 3-D Printing/Advanced Manufacturing (3)
- Artificial Intelligence (1)
- Bioenergy (2)
- Biology (1)
- Biomedical (2)
- Chemical Sciences (2)
- Climate Change (1)
- Composites (3)
- Computer Science (3)
- Critical Materials (1)
- Energy Storage (2)
- Frontier (1)
- Fusion (2)
- Grid (1)
- ITER (1)
- Materials (6)
- Materials Science (9)
- Microscopy (8)
- Nanotechnology (10)
- Nuclear Energy (1)
- Physics (4)
- Quantum Computing (1)
- Quantum Science (2)
- Transportation (1)
Media Contacts
A tiny vial of gray powder produced at the Department of Energy’s Oak Ridge National Laboratory is the backbone of a new experiment to study the intense magnetic fields created in nuclear collisions.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
“Made in the USA.” That can now be said of the radioactive isotope molybdenum-99 (Mo-99), last made in the United States in the late 1980s. Its short-lived decay product, technetium-99m (Tc-99m), is the most widely used radioisotope in medical diagnostic imaging. Tc-99m is best known ...